Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Kenneth McCall, published a paper in 2025 finding that compounded GLP-1s were linked to higher rates of adverse effects than non-compounded products between 2018 and 2024, including more abdominal pain, diarrhea, and nausea
83 amino acids Modifications: Arg substitution (GluArg at IGF-1 position 3) for reduced IGFBP-3 affinity
The dual agonism of tirzepatide thus leverages these complementary actions for a more comprehensive impact on glycemic control and weight reduction compared to GLP-1 agonism alone
Thank you for your interest in our RegActiv products
US$ 24.47
US$ 29.65
US$ 21.23
